NCT06007846View on ClinicalTrials.gov

A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions
Hepatocellular CarcinomaCirrhosis
Interventions
DRUG

Namenda

Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily

Trial Locations (2)

22031

RECRUITING

Inova Schar Cancer Institute, Fairfax

22042

NOT_YET_RECRUITING

Inova Health Care Service, Falls Church

Sponsors
All Listed Sponsors
lead

Inova Health Care Services

OTHER